case_images: PMC10466799_01
case_images: PET-CT scans from initial presentation in october 2021. (A, B) The patient presents with a 18F-fluourodeoxyglucose (FDG)-positive lesion in the left superior lobe and an ipsilateral pleural effusion. (C) ipsilateral FDG positive lymphnode in the aortopulmonary window. (D, E) FDG positive bone lesions in the 10th thoracic vertebra (D) and the 2nd lumbar vertebra (E), resulting in a clinical classification of T1 N1 M1c, Stage IVB, according to the 8th UICC edition.
case_images: fonc-13-1182391-g001.jpg
case_images: PMC10466799_01_fonc-13-1182391-g001.jpg
case_images: f1
case_images: Figure 1 ). Finally, the histology of the tumor was obtained through drainage of a pleural effusion of the left lung.
case_images: Timeline. Maximum diameters of lesion at diagnosis in 10/21: 15 x 23 mm, at PD (progressive disease) in 12/21: 18 x 30 mm, at PR (partial remission) in 01/22: 14 x 27 mm, and at PD 11/22: 37 x 41 mm. SD (stable disease).
case_images: fonc-13-1182391-g002.jpg
case_images: PMC10466799_01_fonc-13-1182391-g002.jpg
case_images: f2
case_images: The therapy was initiated in late November 2022 and consisted of Carboplatin AUC 5 (550mg absolute dose), Pemetrexed 500 mg/m2 and Pembrolizumab 200mg administered every three weeks ( Figure 2 ).